Genetic Testing Firms May Retreat From Uncertain Regulatory Path – Q&A
This article was originally published in The Gray Sheet
Executive Summary
For targeted diagnostics, such as those that predict a person's responsiveness to a drug or treatment, regulatory uncertainty could be driving away investment, says the head of one leading genomic testing firm